Novo Nordisk's GLP-1 receptor ... alcohol use disorder (AUD) reduce the amount they drink – pointing to yet another potential use for the versatile drug class. The small, 48-subject study ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people with early-stage Alzheimer's has shown that the drug was able to reduce shrinking in the areas of ...

Higher body appreciation was highlighted as a protective factor against GLP-1 use. However, it is important to note that the study's cross-sectional design means these findings are correlational ...

Orforglipron significantly reduced HbA1c levels by 1.3% (3mg), 1.6% (12mg), and 1.5% (36mg) compared with 0.1% in the placebo arm. Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1 ...

Share on Pinterest A new study shows GLP-1 drugs liraglutide ... Wegovy is approved for use in weight management. Semaglutide drugs are available as both oral tablets and injections.

Tirzepatide use increased significantly since January ... The GLMs assessed in the study include GLP-1 receptor agonists, sodium-glucose cotransporter-2 (SGLT2) inhibitors, metformin, insulin ...

This retrospective study suggests there is a cardioprotective effect of GLP-1RA compared ... antiarrhythmic drug use, cardioversion, or repeat ablation by 1 year. Similarly, in PULSED AF, around ...

The observational, real-life retrospective cohort study found that in adults with obesity and type 2 diabetes but no prior heart disease, glucagon-like peptide-1 receptor agonists (GLP-1RAs ...

“I’ve been working with GLP-1 ... shows semaglutide can be an effective tool to treat this advanced liver disease.” Ozempic Could Be Lifesaving for Thousands of Americans a Year, Study ...

Treatment satisfaction significantly improved among GLP-1 users in six studies. Breit said the review shows ... use of GLP-1s with the indication to treat mental illness,” Breit said. “Future ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the announcement that its newest GLP-1 drug ... Achieve-1 study was done ...